Evaluation of the Performance of PCR and Hybrid Capture 2 in the Detection of Human Papillomavirus Associated with Cervical Cancer in Algeria
Cancer Research Journal
Volume 6, Issue 3, September 2018, Pages: 84-91
Received: May 28, 2018; Accepted: Jul. 2, 2018; Published: Jul. 27, 2018
Views 369      Downloads 14
Authors
Melhag Mohamed, Biology Department, Faculty of Science of Nature and Life, University of Oran 1 Ahmed Ben Bella, Oran, Algeria
Kerroucha Rabah, Biology Department, Faculty of Science of Nature and Life, University of Oran 1 Ahmed Ben Bella, Oran, Algeria
Melouli Hamid, Institut Pasteur of Algeria, Algiers, Algeria
Midoun Nori, Department of Epidemiology and Preventive Medicine, EHU of Oran, Oran, Algeria
Zemour Lakhdar, Department of Epidemiology and Preventive Medicine, EHU of Oran, Oran, Algeria
Ayyach Ghassan, Gynecology-Obstetrics Department. EPH of Zeralda, Algiers Algeria
Asselah Fatima, Pathology Department, Mustapha Pasha University Hospital, Algiers, Algeria
Bendissari Kheira, Pathology Department, Beni Messous University Hospital, Algiers, Algeria
EL Kebir Fatima Zohra, Biology Department, Faculty of Science of Nature and Life, University of Oran 1 Ahmed Ben Bella, Oran, Algeria
Article Tools
Follow on us
Abstract
To evaluate and compare the performance of PCR (polymerase chain reaction) and second-generation capture hybridization (HC2) in the detection of high-risk Human Papillomavirus (HPV-HR) and to estimate their prevalence among normal cervical, dysplastic and cervical cancer in the Algerian population. 264 women were subjected to cyto-histological and colposcopic diagnostics and to the HPV test by PCR and Hybrid capture 2. The search for HPV DNA by conventional PCR was carried out with MY09 / 11 consensus primers and the typing of HPV with the hybridization technique in solution, Digene Sharp Signal for PCR. Hybrid Capture® 2 was performed with the digene HPV HC2 DNA Test kit. The PCR and HC2 performance tests included sensitivity, specificity, positive and negative predictive values, Youden's index, and Yule's Q coefficient. HPV-HR research has shown that these viruses are associated with 100% high-grade lesions, 88.2% by PCR and 83.3% by HC2 (p = 0.8) with invasive cancer. The PCR and HC2 performance tests were in favor of HCV HPV testing which was more sensitive, more specific, more predictive and more effective. The results on the prevalence of HPV-HR associated with cervical lesions are comparable to those in the literature. In comparison with PCR, the capture hybridization technique 2 is recommended for HPV diagnosis because of its better performance and simplicity.
Keywords
Cervical Cancer, Precancerous Lesions, Prevalence, HPV Testing, PCR, Capture Hybridization 2
To cite this article
Melhag Mohamed, Kerroucha Rabah, Melouli Hamid, Midoun Nori, Zemour Lakhdar, Ayyach Ghassan, Asselah Fatima, Bendissari Kheira, EL Kebir Fatima Zohra, Evaluation of the Performance of PCR and Hybrid Capture 2 in the Detection of Human Papillomavirus Associated with Cervical Cancer in Algeria, Cancer Research Journal. Vol. 6, No. 3, 2018, pp. 84-91. doi: 10.11648/j.crj.20180603.13
Copyright
Copyright © 2018 Authors retain the copyright of this article.
This article is an open access article distributed under the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
References
[1]
Ferlay J, Soerjomataram I, Dikshit R, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer 2015; 136: E359-386.
[2]
Ho G, Burk R, Klein S, Kadish A, Chang C, Palan P, et al. Persistent genital human papillomavirus infection as a risk factor for persistent cervical dysplasia. J Natl Cancer Inst 87 (1995), 1365–71.
[3]
Koshiol J, Lindsay L, Pimenta J, Poole C, Jenkins D, and Smith J. Persistent human papillomavirus infection and cervical neoplasia: a systematic review and metaanalysis. Am J Epidemiol 168 (2008), 123–37.
[4]
Sadouki N, Boudriche A, Khenchouche A, Benyacoub D, Djennaoui T, Boudriche H, et al. Détection des papillomavirus à haut risque dans les lésions précancéreuses du col en Algérie; état des lieux et perspective. Arch Inst Pasteur Alger T 67 (2010), 53–82.
[5]
Brink AA, Snijders P CJ, Berkhof J, Verheijen RH. HPV testing in cervical screening. Best Pract Res Clin Obstet Gynécol 2006; 20: 253-66.
[6]
Cuzick J, Mayrand MH, Ronco G, Snijders P, Wardle J. Chapter 10: New dimensions in cervical cancer screening. Vaccine 2006; 24 Suppl 3: S3/90-7.
[7]
Wells M, Ostor AG, Crum CP, Franceschi S, Tommasino M, Nesland JM, et al. Tumors’ of the breast end female genital organs. Lyon: IARC Press, 2003.
[8]
Sankaranarayanan R, et al (2009) HPV Screening for Cervical Cancer in Rural India. N. Engl. J. Med. 360, 1385-1394.
[9]
Snijders PJ, van den Brule AJ, Schrijnemakers HF, Snow G, Meijer CJ, Walboomers JM. The use of general primers in the polymerase chain reaction permits the detection of a broad spectrum of human papillomavirus genotypes. J Gen Virol 1990; 71: 173-81.
[10]
Fédération des Gynécologues et Obstétriciens de Langue Française. Conférence de consensus sur le dépistage du cancer du col utérin, Lille 5-6-7-8 septembre 1990. Recommandations. J Gynécol Obstét Biol Reprod 1990;19:1
[11]
Haute Autorité de Santé (HAS) – Dépistage et prévention du cancer du col de l’utérus Actualisation du référentiel de pratiques de l’examen périodique de santé (EPS) Juin 2013-Referentiel-KC Uterus juin 2013 – N° ISBN: 978-2-11-128544-6
[12]
Monsonego J. Cervical cancer prevention: the impact of HPV vaccination. Gynecol Obstet Fertil 2006 Mar; 34(3):189-201.
[13]
Moscicki AB, Schiffman M, Kjaer S, Villa LL. Chapter 5: Updating the natural history of HPV and anogénitale cancer. Vaccine 2006 Aug 21; 24 Suppl 3:S42-S51.
[14]
Ostor AG. Natural history of cervical intraepithelial neoplasia: a critical review. Int J Gynecol Pathol 1993 Apr; 12(2):186-92.
[15]
Schlecht NF, Platt RW, Duarte-Franco E, Costa MC, Sobrinho JP, Prado JC, et al. Human papillomavirus infection and time to progression and regression of cervical intraepithelial neoplasia. J Natl Cancer Inst 2003 Sep 3; 95 (17):1336-43.
[16]
Halfon P, Lindemann M, Raimondo A, Ravet S, Camus C, Khiri H, Pénaranda G, Sideri M, and Sandri M. HPV genotype distribution according to severity of cervical neoplasia using the Digene HPV genotyping LQ test. Arch Virol 158 (2013), 1143–9.
[17]
Mergui J, Polena V, David-Montefiore E, and Uzan S. Recommandations pour la surveillance des patientes traitées pour des lésions de haut grade du col utérin. J Gynecol Obstet Biol Reprod (Paris) 37 (2008), S121–30.
[18]
Beby-Defaux A, Bourgoin A, Ragot S, Battandier D, Lemasson JM, Renaud O, et al. Human papillomavirus infection of the cervix uteri in women attending a Health Examination Center of the French social security. J Med Virol 2004 Jun; 73 (2):262-8.
[19]
Dalstein V, Riethmuller D, Sautiere JL, Pretet JL, Kantelip B, Schaal JP, et al. Detection of cervical precancer and cancer in a hospital population; benefits of testing for human papillomavirus. Eur J Cancer 2004 May; 40(8):1225-32.
[20]
Bruni L, Diaz M, Castellsague´ X, et al. Cervical human papillomavirus prevalence in 5 continents: meta-analysis of 1 million women with normal cytological findings. J Infect Dis 2010; 202: 1789-99.
[21]
Baseman JG, Koutsky LA. The epidemiology of human papillomavirus infections. J Clin Virol 2005 Mar; 32 Suppl 1:S16-S24.
[22]
Riethmuller D, Schaal JP, Mougin C. [Epidemiology and natural history of genital infection by human papillomavirus]. Gynecol Obstet Fertil 2002 Feb; 30(2):139-46.
[23]
Ho GY, Bierman R, Beardsley L, Chang CJ, Burk RD. Natural history of cervicovaginal papillomavirus infection in young women. N Engl J Med 1998 Feb 12; 338(7):423-8.
[24]
Levert M, Clavel C, Graesslin O, Masure, M, Birembaut P, Quereux C, and Gabriel R. Typage des Papillomavirus humains dans les frottis cervicaux de routine. Résultats sur une série de 3 778 patientes. Gynécol Obstét et Fertil 28 (2000), 722–8.
[25]
Nahiba Missaoui, Sihem Hmissa, Amel Trabelsi, Mohamed Tahar acoubi, Amel Nouira, Lucien Frappart, et al. Prévalence des infections à papillomavirus (HPV) dans les lésions précancéreuses et cancéreuses du col utérin en Tunisie. Ann Biol Clin 2010; 68 (3): 297-303.
[26]
ANAES. Evaluation de l’intérêt de la recherché des papillomavirus humains (HPV) dans le dépistage des lésions précancéreuses et cancéreuses du col de l’utérus. Tech. rep., Agence nationale d’accréditation et d’évaluation en santé, France, 2004.
[27]
Elgnaoui N, Gazzaz B, Khyati M, Benchakroun N, Benidder A, Hassar M, et al. Rôle des papillomavirus humains (HPV) dans le cancer du col utérin au Maroc et facteurs associés. Journal Biologie et Santé de Casablanca (JBS 2004); Décembre 2004: 15-16
[28]
Fahey M, Irwig L, and Macaskill P. Meta-analysis of Pap test accuracy. Am J Epidemiol 141 (1995), 680–9.
[29]
Koliopoulos G, Arbyn M, Martin-Hirsch P, Kyrgiou M, Prendiville W, and Praskevaidis E. Diagnostic accuracy of human papillomavirus testing in primary cervical screening. A systematic review and meta-analysis of non-randomized study. Gynecol Oncol 104 (2007), 232–46.
[30]
Cuzick J, Clavel C, Petry K, Meijer C, Hoyer H, Ratnam S, et al. Overview of the European and North American studies on HPV testing in primary cervical cancer screening. Int J Cancer 119 (2006), 1095–101.
[31]
Jeronimo J, Bansil P, Lim J, Peck R, Paul P, Amador J, et al. A multicountry evaluation of care HPV testing, visual inspection with acetic acid, and Papanicolaou testing for the detection of cervical cancer. Int J Gynecol Cancer 24 (2014), 576–85.
[32]
Cuzick J, Arbyn M, Sankararayanan R, Tsu U, Ronco G, Mayrand M, et al. Overview of human papillomavirus based and other novel option for cervical cancer screening in developed and developing countries. Vaccine 265 (2008), K29–K41.
[33]
Monsonego J. Traité des infections et pathologies génitales à papillomavirus. Springer-Verlag Paris, France, 2007.
[34]
Clavel C, Masure M, Bory JP, et al. Human papillomavirus testing in primary screening for the detection of high-grade cervical lesions: a study of 7932 women. Br J Cancer 2001; 84: 1616-23.
[35]
Bory JP, Cucherousset J, Lorenzato M, et al. Recurrent human papillomavirus infection detected with the hybrid capture II assay selects women with normal cervical smears at risk for developing high grade cervical lesions: a longitudinal study of 3,091 women. Int J Cancer 2002; 102: 519-25.
[36]
Monsonego J. Test HPV et prévention du cancer du col utérin: pratiques et tendances actuelles. Ann Biol Clin 2013; 71(spécial 1): 27-32 doi:10. 1684/abc. 2013. 0907
[37]
Bhatla N, and Moda N. The clinical utility of HPV DNA testing in cervical cancer screening strategies. Indian J Med Res 130 (2009), 261–5.
[38]
INESSS (Institut national d’excellence en santé et en services sociaux. Comparaison des stratégies de dépistage du cancer du col de l’utérus avec le test de détection des virus de papillome humain (test VPH) ou la cytologie gynécologique (test PAP). État des connaissances rédigé par Julie Lessard, Khalil Moqadem, Patricia Goggin et Marie-Hélène Mayrand. Québec, Qc: INESSS; 2017. 58p.
[39]
Zhao X, et al. The performance of human papillomavirus DNA detection with type 16/18 genotyping by hybrid capture in primary test of cervical cancer screening: a cross-sectional study in 10,669 Chinese women, Clinical Microbiology and Infection (2018), https://doi.org/10.1016/j.cmi.2018.02.027
ADDRESS
Science Publishing Group
548 FASHION AVENUE
NEW YORK, NY 10018
U.S.A.
Tel: (001)347-688-8931